Clinical trial
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to…
NCT02951052 · ViiV Healthcare, Industry · Active, not recruiting
Key facts
| NCT number | NCT02951052 |
|---|---|
| Title | Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults |
| Official title | A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who… |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | Janssen Pharmaceuticals Industry GlaxoSmithKline |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus, HIV Infections |
| Intervention type | Drug |
| Interventions | Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI |
| Enrollment | 618 |
| Start date | Oct 28, 2016 |
| Primary completion | May 29, 2018 |
| Completion | Dec 31, 2029 |
| First posted | Nov 1, 2016 |
| Last update posted | Dec 31, 2025 |
| Countries | Argentina, Australia, Canada, France, Germany, Italy, Mexico, Russia, South Africa, South Korea, Spain, Sweden and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: